A
Avalyn Pharma Inc D
D
AVLN
27.120
USD
-0.04
(-0.15%)
Market Closed
Volume
15,083
EPS
0
Div Yield
-
P/E
-12
Market Cap
1,202,313,536
Title: Avalyn Pharma Inc
Sector: Healthcare
Industry: Biotechnology
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, whichare inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.